Chr. Hansen A/S was founded in 1874 by the Danish pharmacist Christian Ditlev Ammentorp Hansen. Since then, Chr. Hansen has continued to revolutionize and set the standards for the manufacture of microbial products. We believe that microbial challenges require microbial solutions. With that in mind, we are the owner of one of the world’s largest commercial collections of bacteria, with around 40,000 strains.
The backbone to our business
With over one hundred years of experience using live microbes in food and feed, our strong foundation enables us to approach innovation through the application of leading science. Not only does this lead to new solutions, but also encourages us to pursue the underlying mechanisms by which our probiotics work.
Our team of more than 200 employees in Innovation is the backbone to our business, bringing a wide range of experience and expertise from a broad set of backgrounds, including veterinarians, microbiologists, agronomists and experts within the fields of genome sequencing and screening – to name but a few.
A science-based approach to Animal Health
Chr. Hansen has supplied live probiotic bacterial solutions to the livestock production industry since the initial introduction of those tools to the market. Our strains and products are the outcome of rigorous science-based research and their benefits are among the best proven and documented in the industry.
The search for a beneficial strain starts in our labs in Hørsholm, Denmark. At Chr. Hansen, we continuously build and expand our strain library with strains from around the world sourced from animals, soils, feeds, plants and food. We have over 28,000 strains in our growing collection and access to thousands more through our partnerships.
From this library, we search for strains with unique features and attributes. Among the most important attributes are those related to beneficial functions in the gastrointestinal tract, like facilitation of digestion of feed and availability of nutrients, inhibition of proliferation of pathogens, and stimulation of the innate immune system of animals. We also look for survivability and ability to colonize the gut and finally we look for strains that can survive a production and formulation process and stay alive until it reaches the animal. For each of these attributes and strain functions we have developed state of the art in-house in-vitro testing systems.
Promising strains are taken to in-vivo testing with our partners and customers, where we confirm in-vitro observations and further investigate how the strains interact with the animals’ gastrointestinal system. In addition to improved performance, we investigate how the strain establishes itself in the animals’ gastrointestinal tract and how those probiotic bacteria interact with the host and its gut microbiome. Promising strains are further tested in state-of-the-art, randomized, statistically-powered, multicenter trials before being submitted for registration.
A strong scientific community
Chr. Hansen has developed a strong collaboration with business partners, research institutions and leading academicians, ensuring our place at the forefront of scientific developments.
But it is undoubtedly our closeness to our customers that ensures that our developments stay relevant, providing solutions that meet customers’ needs – helping us to understand local and market challenges, regulation and developments, and enabling us to take our science-based innovations from idea generation to producing quality products.
By truly understanding how our solutions work, as well as the needs of our individual customers, we bring the right solutions to the right customers.